𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD

✍ Scribed by Gerald Schulman; Rajiv Agarwal; Muralidhar Acharya; Tomas Berl; Samuel Blumenthal; Nelson Kopyt

Book ID
114467368
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
220 KB
Volume
47
Category
Article
ISSN
0272-6386

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fontolizumab in moderate to severe Crohn
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
✍ Walter Reinisch; Williem de Villiers; LΓ‘szlΓ³ Bene; LΓ‘szlΓ³ Simon; IstvΓ‘n RΓ‘cz; Se πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 285 KB

## Background: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptom

A phase II, randomized, double-blind, pl
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
✍ Wallace, Daniel J. ;Stohl, William ;Furie, Richard A. ;Lisse, Jeffrey R. ;McKay, πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 372 KB πŸ‘ 2 views

## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National